Arrowhead Pharmaceuticals Inc
ARWRToday
-9.48%
5 Days
-15.43%
1 Month
-15.72%
6 Months
+32.64%
Year to Date
+9.99%
1 Year
+145.69%
Key Figures
• Arrowhead shares dropped despite positive Phase 1/2a data for ARO-DIMER-PA due to profit-taking. • The company reported annual revenue of $829.45M with a net loss of $1.63M. • Technical indicators show a MACD sell signal and an RSI of 27.985.
• Arrowhead Pharmaceuticals shares rose following positive Phase 3 clinical trial results. • Analysts increased price targets based on successful clinical data and market potential. • Technical indicators currently provide sell signals despite recent positive fundamental developments.
• Investor sentiment shifted due to pipeline concerns and intensified competition in RNAi therapeutics. • Potential equity dilution and macroeconomic uncertainty are pressuring Arrowhead Pharmaceuticals' near-term stock performance. • Arrowhead reported annual revenue of $829.45 million with a net loss of $1.63 million.
Arrowhead Pharmaceuticals Inc's Score
Media Coverage
Analyst Rating
Arrowhead Pharmaceuticals Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Arrowhead Pharmaceuticals Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 13.72% |
| Avoro Capital Advisors LLC | 7.54% |
| Vanguard Portfolio Management, LLC | 5.07% |
| Fidelity Management & Research Company LLC | 4.63% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 42.06% |
| Investment Advisor/Hedge Fund | 29.41% |
| Hedge Fund | 7.57% |
| Individual Investor | 3.76% |
Related Instruments
Popular Instruments
